Page Title
Drug Development Pipeline
SPI-1005
Status
Phase TwoTherapeutic Approach
Anti-Infective
SPI-1005 is an oral form of the drug ebselen. Ebselen is a molecule designed to mimic the function of a key enzyme found in the inner ear, glutathione peroxidase (GPx). Regular use of aminoglycoside antibiotics can cause damaging side effects in the inner ear. By mimicking the function of GPx, SPI-1005 may protect the inner ear from damage.
Status
A Phase 2 study to test the safety and tolerability of SPI-1005 in people with CF is currently underway.
Sponsor
This program is sponsored by Sound Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation.
Recent SPI-1005 Studies
-
Closed to Enrollment
Study of SPI-1005 in people with CF ages 18 and older (Sound Pharma SPI-3005-501.2)

CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More